AngioSoma, Inc. (OTC: SOAN) Announces Agreement with Esther & Esther, Inc. to Maximize Sales of Its OTC Products with Existing Online Marketing Platform

Houston, TX, September 18, 2017 (PR.com) – AngioSoma, Inc. (OTC: SOAN) announces Agreement with Esther & Esther, Inc. to maximize sales of its OTC products with existing online marketing platform. Conjunctionally, the company’s subsidiary, Soma Nutraceuticals Inc., completed a licensing agreement with Kentucky-based East Kentucky Organic, Inc. to begin manufacturing of Soma Nutraceutical’s product line, Read more about AngioSoma, Inc. (OTC: SOAN) Announces Agreement with Esther & Esther, Inc. to Maximize Sales of Its OTC Products with Existing Online Marketing Platform[…]

AngioSoma’s Corporate Focus

July 14, 2016 09:00 AM Eastern Daylight Time MONTGOMERY, Texas–(BUSINESS WIRE)–AngioSoma, Inc. (OTCQB:SOAN), previously known as First Titan Corp. (the ‘Company‘, ‘we‘, and ‘our‘), changed our corporate name and focus to that of a clinical stage biopharmaceutical company introducing an exciting new treatment for one of the world’s most insidious and pervasive diseases, peripheral artery Read more about AngioSoma’s Corporate Focus[…]

First Titan Corp. Acquired AngioSoma, Inc.

HOUSTON, TX / ACCESSWIRE / June 22, 2016 / First Titan Corp. (OTCQB: FTTN) (the “First Titan”) is proud to announce the acquisition of AngioSoma, Inc., (OTCQB: SOAN) (the “Company”). The acquisition of AngioSoma, Inc. provides diversification for First Titan outside of the depressed oil & gas industry under the new name AngioSoma, Inc. and Read more about First Titan Corp. Acquired AngioSoma, Inc.[…]